Skin barrier and immune dysregulation in atopic dermatitis: An evolving story with important clinical implications

Journal of Allergy and Clinical Immunology: In Practice

Volumn 2, Issue 4, 2014, Pages 371-379

  Czarnowicki, Tali ^a   Krueger, James G ^a   Guttman Yassky, Emma ^a,b  

^a ROCKEFELLER UNIVERSITY   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Atopic dermatitis; Extrinsic atopic dermatitis; Immune dysregulation; Intrinsic atopic dermatitis; Microbiome; Proactive treatment; Residual disease genomic profile; Skin barrier

Indexed keywords

BETA DEFENSIN; CALCINEURIN INHIBITOR; CORTICOSTEROID; FILAGGRIN; INTERLEUKIN 13; INTERLEUKIN 22; INTERLEUKIN 31; INTERLEUKIN 4; INTERLEUKIN 6; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; POLYPEPTIDE ANTIBIOTIC AGENT; ROSIGLITAZONE; SERINE PROTEINASE INHIBITOR; STAPHYLOCOCCUS ENTEROTOXIN B; STAT3 PROTEIN; SUPERANTIGEN; TOXIC SHOCK SYNDROME TOXIN 1; CYTOKINE;

ARTICLE; ATOPIC DERMATITIS; CHROMOSOME; ENVIRONMENTAL FACTOR; GENETIC CODE; GENETIC VARIABILITY; HEREDITY; HUMAN; IMMUNE DYSREGULATION; INNATE IMMUNITY; PATHOGENESIS; PHENOTYPE; PREVALENCE; TH17 CELL; ANIMAL; DERMATITIS, ATOPIC; HOMEOSTASIS; IMMUNITY; IMMUNOLOGY; METABOLISM; PATHOLOGY; PERSONALIZED MEDICINE; SKIN; TH1 TH2 BALANCE;

ANIMALS; CYTOKINES; DERMATITIS, ATOPIC; HOMEOSTASIS; HUMANS; IMMUNITY; INDIVIDUALIZED MEDICINE; SKIN; TH1-TH2 BALANCE; TH17 CELLS;

EID: 84904049668     PISSN: 22132198     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaip.2014.03.006     Document Type: Article

References (135)

1. Thappa D.M., Malathi M. Is there something called adult onset atopic dermatitis in India?. Indian J Dermatol Venereol Leprol 2013, 79:145-147.
2. Bieber T. Atopic dermatitis. NEngl J Med 2008, 358:1483-1494.
3. Elias P.M., Hatano Y., Williams M.L. Basis for the barrier abnormality in atopic dermatitis: outside-inside-outside pathogenic mechanisms. JAllergy Clin Immunol 2008, 121:1337-1343.
4. Guttman-Yassky E., Nograles K.E., Krueger J.G. Contrasting pathogenesis of atopic dermatitis and psoriasis-part I: clinical and pathologic concepts. JAllergy Clin Immunol 2011, 127:1110-1118.
5. Boguniewicz M., Leung D.Y.M. Recent insights into atopic dermatitis and implications for management of infectious complications. JAllergy Clin Immunol 2010, 125:4-13.
6. Elias P.M., Steinhoff M. "Outside-to-inside" (and now back to "outside") pathogenic mechanisms in atopic dermatitis. JInvest Dermatol 2008, 128:1067-1070.
7. McAleer M.A., Irvine A.D. The multifunctional role of filaggrin in allergic skin disease. JAllergy Clin Immunol 2013, 131:280-291.
8. Bieber T., Novak N. Pathogenesis of atopic dermatitis: new developments. Curr Allergy Asthma Rep 2009, 9:291-294.
9. Gittler J.K., Shemer A., Suarez-Farinas M., Fuentes-Duculan J., Gulewicz K.J., Wang C.Q.F., et al. Progressive activation of T(H)2/T(H)22 cytokines and selective epidermal proteins characterizes acute and chronic atopic dermatitis. JAllergy Clin Immunol 2012, 130:1344-1354.
10. Hanifin J.M. Evolving concepts of pathogenesis in atopic dermatitis and other eczemas. JInvest Dermatol 2009, 129:320-322.
11. Taieb A., Hanifin J., Cooper K., Bos J.D., Imokawa G., David T.J., et al. Proceedings of the 4th Georg Rajka International Symposium on Atopic Dermatitis, Arcachon, France, September 15-17, 2005. JAllergy Clin Immunol 2006, 117:378-390.
12. Mischke D., Korge B.P., Marenholz I., Volz A., Ziegler A. Genes encoding structural proteins of epidermal cornification and S100 calcium-binding proteins form a gene complex ("epidermal differentiation complex") on human chromosome 1q21. JInvest Dermatol 1996, 106:989-992.
13. Volz A., Korge B.P., Compton J.G., Ziegler A., Steinert P.M., Mischke D. Physical mapping of a functional cluster of epidermal differentiation genes on chromosome-1q21. Genomics 1993, 18:92-99.
14. Candi E., Schmidt R., Melino G. The cornified envelope: a model of cell death in the skin. Nat Rev Mol Cell Biol 2005, 6:328-340.
15. Barnes K.C. An update on the genetics of atopic dermatitis: scratching the surface in 2009. JAllergy Clin Immunol 2010, 125:16-29.e1-11. quiz 30-1.
16. O'Regan G.M., Sandilands A., McLean W.H., Irvine A.D. Filaggrin in atopic dermatitis. JAllergy Clin Immunol 2008, 122:689-693.
17. Rawlings A.V., Harding C.R. Moisturization and skin barrier function. Dermatol Ther 2004, 17(Suppl 1):43-48.
18. Boguniewicz M., Leung D.Y.M. Atopic dermatitis: a disease of altered skin barrier and immune dysregulation. Immunol Rev 2011, 242:233-246.
19. Brown S.J., Relton C.L., Liao H.H., Zhao Y.W., Sandilands A., Wilson I.J., et al. Filaggrin null mutations and childhood atopic eczema: a population-based case-control study. JAllergy Clin Immunol 2008, 121:940-946.
20. Palmer C.N.A., Irvine A.D., Terron-Kwiatkowski A., Zhao Y.W., Liao H.H., Lee S.P., et al. Common loss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis. Nat Genet 2006, 38:441-446.
21. Baurecht H., Irvine A.D., Novak N., Illig T., Buhler B., Ring J., et al. Toward a major risk factor for atopic eczema: Meta-analysis of filaggrin polymorphism data. JAllergy Clin Immunol 2007, 120:1406-1412.
22. Henderson J., Northstone K., Lee S.P., Liao H., Zhao Y., Pembrey M., et al. The burden of disease associated with filaggrin mutations: a population-based, longitudinal birth cohort study. JAllergy Clin Immunol 2008, 121:872-877.e9.
23. Leung D.Y.M. Our evolving understanding of the functional role of filaggrin in atopic dermatitis. JAllergy Clin Immunol 2009, 124:494-495.
24. Guttman-Yassky E., Suarez-Farinas M., Chiricozzi A., Nograles K.E., Shemer A., Fuentes-Duculan J., et al. Broad defects in epidermal cornification in atopic dermatitis identified through genomic analysis. JAllergy Clin Immunol 2009, 124:1235-1244.
25. Lederberg J., McCray A.T. 'Ome sweet 'omics: a genealogical treasury of words. Scientist 2001, 15:8-9.
26. NIH HMP Group Working Group, Peterson J., Garges S., Giovanni M., McInnes P., Wang L., et al. The NIH Human Microbiome Project. Genome Res 2009, 19:2317-2323.
27. Kong H.H., Segre J.A. Skin microbiome: looking back to move forward. JInvest Dermatol 2012, 132:933-939.
28. Ong P.Y., Ohtake T., Brandt C., Strickland I., Boguniewicz M., Ganz T., et al. Endogenous antimicrobial peptides and skin infections in atopic dermatitis. NEngl J Med 2002, 347:1151-1160.
29. Agner T. Staphylococcal-mediated worsening of atopic dermatitis: many players involved. Br J Dermatol 2010, 163:1147.
30. Higaki S., Morohashi M., Yamagishi T., Hasegawa Y. Comparative study of staphylococci from the skin of atopic dermatitis patients and from healthy subjects. Int J Dermatol 1999, 38:265-269.
31. Cho S.H., Strickland I., Boguniewicz M., Leung D.Y.M. Fibronectin and fibrinogen contribute to the enhanced binding of Staphylococcus aureus to atopic skin. JAllergy Clin Immunol 2001, 108:269-274.
32. Nomura I., Goleva E., Howell M.D., Hamid Q.A., Ong P.Y., Hall C.F., et al. Cytokine milieu of atopic dermatitis, as compared to psoriasis, skin prevents induction of innate immune response genes. JImmunol 2003, 171:3262-3269.
33. Howell M.D., Fairchild H.R., Kim B.E., Bin L.H., Boguniewicz M., Redzic J.S., et al. Th2 cytokines act on S100/A11 to downregulate keratinocyte differentiation. JInvest Dermatol 2008, 128:2248-2258.
34. Bieber T. Atopic dermatitis. Ann Dermatol 2010, 22:125-137.
35. Jensen J.M., Pfeiffer S., Akaki T., Schroder J.M., Kleine M., Neumann C., et al. Barrier function, epidermal differentiation, and human beta-defensin 2 expression in tinea corporis. JInvest Dermatol 2007, 127:1720-1727.
36. Clausen M.L., Jungersted J.M., Andersen P.S., Slotved H.C., Krogfelt K.A., Agner T. Human beta-defensin-2 as a marker for disease severity and skin barrier properties in atopic dermatitis. Br J Dermatol 2013, 169:587-593.
37. Brauweiler AM, Goleva E, Leung DY. Th2 Cytokines Increase Staphylococcus aureus alpha toxin induced keratinocyte death through the Signal Transducer and Activator of Transcription 6 (STAT6). J Invest Dermatol (27 January 2014) Epub ahead of print. doi:10.1038/jid.2014.43.
38. Sonkoly E., Muller A., Lauerma A.I., Pivarcsi A., Soto H., Kemeny L., et al. IL-31: a new link between T cells and pruritus in atopic skin inflammation. JAllergy Clin Immunol 2006, 117:411-417.
39. Cornelissen C., Marquardt Y., Czaja K., Wenzel J., Frank J., Luscher-Firzlaff J., et al. IL-31 regulates differentiation and filaggrin expression in human organotypic skin models. JAllergy Clin Immunol 2012, 129:426-433. 33.e1-8.
40. Wolk K., Kunz S., Witte E., Friedrich M., Asadullah K., Sabat R. IL-22 increases the innate immunity of tissues. Immunity 2004, 21:241-254.
41. Sa S.M., Valdez P.A., Wu J.F., Jung K., Zhong F., Hall L., et al. The effects of IL-20 subfamily cytokines on reconstituted human epidermis suggest potential roles in cutaneous innate defense and pathogenic adaptive immunity in psoriasis. JImmunol 2007, 178:2229-2240.
42. Witte E., Witte K., Warszawska K., Sabat R., Wolk K. Interleukin-22: a cytokine produced by T, NK and NKT cell subsets, with importance in the innate immune defense and tissue protection. Cytokine Growth Factor Rev 2010, 21:365-379.
43. Wolk K., Witte E., Wallace E., Docke W.D., Kunz S., Asadullah K., et al. IL-22 regulates the expression of genes responsible for antimicrobial defense, cellular differentiation, and mobility in keratinocytes: a potential role in psoriasis. Eur J Immunol 2006, 36:1309-1323.
44. Kao C.Y., Chen Y., Thai P., Wachi S., Huang F., Kim C., et al. IL-17 markedly up-regulates beta-defensin-2 expression in human airway epithelium via JAK and NF-kappaB signaling pathways. JImmunol 2004, 173:3482-3491.
45. Stark M.A., Huo Y., Burcin T.L., Morris M.A., Olson T.S., Ley K. Phagocytosis of apoptotic neutrophils regulates granulopoiesis via IL-23 and IL-17. Immunity 2005, 22:285-294.
46. Guttman-Yassky E., Lowes M.A., Fuentes-Duculan J., Zaba L.C., Cardinale I., Nograles K.E., et al. Low expression of the IL-23/Th17 pathway in atopic dermatitis compared to psoriasis. JImmunol 2008, 181:7420-7427.
47. Wolk K., Witte K., Witte E., Raftery M., Kokolakis G., Philipp S., et al. IL-29 is produced by T(H)17 cells and mediates the cutaneous antiviral competence in psoriasis. Sci Transl Med 2013, 5:204ra129.
48. Bunikowski R., Mielke M.E.A., Skarabis H., Worm M., Anagnostopoulos I., Kolde G., et al. Evidence for a disease-promoting effect of Staphylococcus aureus-derived exotoxins in atopic dermatitis. JAllergy Clin Immunol 2000, 105:814-819.
49. Cork M.J., Danby S.G., Vasilopoulos Y., Hadgraft J., Lane M.E., Moustafa M., et al. Epidermal barrier dysfunction in atopic dermatitis. JInvest Dermatol 2009, 129:1892-1908.
50. Son E.D., Kim H.J., Park T., Shin K., Bae I.H., Lim K.M., et al. Staphylococcus aureus inhibits terminal differentiation of normal human keratinocytes by stimulating interleukin-6 secretion. JDermatol Sci 2014, 74:64-71.
51. Hosoki K., Nakamura A., Nagao M., Hiraguchi Y., Tanida H., Tokuda R., et al. Staphylococcus aureus directly activates eosinophils via platelet-activating factor receptor. JLeukoc Biol 2012, 92:333-341.
52. Nada H.A., Gomaa N.I., Elakhras A., Wasfy R., Baker R.A. Skin colonization by superantigen-producing Staphylococcus aureus in Egyptian patients with atopic dermatitis and its relation to disease severity and serum interleukin-4 level. Int J Infect Dis 2012, 16:e29-e33.
53. Niebuhr M., Scharonow H., Gathmann M., Mamerow D., Werfel T. Staphylococcal exotoxins are strong inducers of IL-22: a potential role in atopic dermatitis. JAllergy Clin Immunol 2010, 126:1176-11783.e4.
54. Bath-Hextall F.J., Birnie A.J., Ravenscroft J.C., Williams H.C. Interventions to reduce Staphylococcus aureus in the management of atopic eczema: an updated Cochrane review. Br J Dermatol 2010, 163:12-26.
55. Boguniewicz M., Sampson H., Leung S.B., Harbeck R., Leung D.Y.M. Effects of cefuroxime axetil on Staphylococcus aureus colonization and superantigen production in atopic dermatitis. JAllergy Clin Immunol 2001, 108:651-652.
56. Boguniewicz M., Leung D.Y. The ABC's of managing patients with severe atopic dermatitis. JAllergy Clin Immunol 2013, 132:511-512.e5.
57. Schittek B. The antimicrobial skin barrier in patients with atopic dermatitis. Curr Probl Dermatol 2011, 41:54-67.
58. Jensen J.M., Pfeiffer S., Witt M., Brautigam M., Neumann C., Weichenthal M., et al. Different effects of pimecrolimus and betamethasone on the skin barrier in patients with atopic dermatitis. JAllergy Clin Immunol 2009, 123:1124-1133.
59. Hung S.H., Lin Y.T., Chu C.Y., Lee C.C., Liang T.C., Yang Y.H., et al. Staphylococcus colonization in atopic dermatitis treated with fluticasone or tacrolimus with or without antibiotics. Ann Allergy Asthma Immunol 2007, 98:51-56.
60. Howell M.D., Boguniewicz M., Pastore S., Novak N., Bieber T., Girolomoni G., et al. Mechanism of HBD-3 deficiency in atopic dermatitis. Clin Immunol 2006, 121:332-338.
61. Boguniewicz M. New strategies for dealing with Staphylococcus aureus colonization and the emerging methicillin-resistant Staphylococcus aureus epidemic in atopic dermatitis. Chem Immul Allery 2012, 96:113-119.
62. Sidbury R., Sullivan A.F., Thadhani R.I., Camargo C.A. Randomized controlled trial of vitamin D supplementation for winter-related atopic dermatitis in Boston: a pilot study. Br J Dermatol 2008, 159:245-247.
63. Savage P.B., Li C.H., Taotafa U., Ding B.W., Guan Q.Y. Antibacterial properties of cationic steroid antibiotics. FEMS Microbiol Lett 2002, 217:1-7.
64. Chin J.N., Rybak M.J., Cheung C.M., Savage P.B. Antimicrobial activities of ceragenins against clinical isolates of resistant Staphylococcus aureus. Antimicrob Agents Chemother 2007, 51:1268-1273.
65. Yang X., Buonpane R.A., Moza B., Rahman A.K., Wang N.Y., Schlievert P.M., et al. Neutralization of multiple staphylococcal superantigens by a single-chain protein consisting of affinity-matured, variable domain repeats. JInfect Dis 2008, 198:344-348.
66. Brown A.F., Leech J.M., Rogers T.R., McLoughlin R.M. Colonization: modulation of host immune response and impact on human vaccine design. Front Immunol 2014, 4:507.
67. Dinarello C.A. Immunological and inflammatory functions of the interleukin-1 family. Ann Rev Immunol 2009, 27:519-550.
68. Sehra S., Yao Y., Howell M.D., Nguyen E.T., Kansas G.S., Leung D.Y., et al. IL-4 regulates skin homeostasis and the predisposition toward allergic skin inflammation. JImmunol 2010, 184:3186-3190.
69. Howell M.D., Kim B.E., Gao P., Grant A.V., Boguniewicz M., DeBenedetto A., et al. Cytokine modulation of atopic dermatitis filaggrin skin expression. JAllergy Clin Immunol 2007, 120:150-155.
70. Kim B.E., Leung D.Y.M., Boguniewicz M., Howell M.D. Loricrin and involucrin expression is down-regulated by Th2 cytokines through STAT-6. Clin Immunol 2008, 126:332-337.
71. Nograles K.E., Zaba L.C., Guttman-Yassky E., Fuentes-Duculan J., Suarez-Farinas M., Cardinale I., et al. Th17 cytokines interleukin (IL)-17 and IL-22 modulate distinct inflammatory and keratinocyte-response pathways. Br J Dermatol 2008, 159:1092-1102.
72. Kurahashi R., Hatano Y., Katagiri K. IL-4 suppresses the recovery of cutaneous permeability barrier functions in vivo. JInvest Dermatol 2008, 128:1329-1331.
73. Hatano Y., Terashi H., Arakawa S., Katagiri K. Interleukin-4 suppresses the enhancement of ceramide synthesis and cutaneous permeability barrier functions induced by tumor necrosis factor-alpha and interferon-gamma in human epidermis. JInvest Dermatol 2005, 124:786-792.
74. Elias P.M. Therapeutic implications of a barrier-based pathogenesis of atopic dermatitis. Ann Dermatol 2010, 22:245-254.
75. Fujita H. The role of IL-22 and Th22 cells in human skin diseases. JDermatol Sci 2013, 72:3-8.
76. Boniface K., Bernard F.X., Garcia M., Gurney A.L., Lecron J.C., Morel F. IL-22 inhibits epidermal differentiation and induces proinflammatory gene expression and migration of human keratinocytes. JImmunol 2005, 174:3695-3702.
77. Liu Y.J. Thymic stromal lymphopoietin: master switch for allergic inflammation. JExp Med 2006, 203:269-273.
78. Ziegler S.F., Liu Y.J. Thymic stromal lymphopoietin in normal and pathogenic T cell development and function. Nat Immunol 2006, 7:709-714.
79. Ito T., Wang Y.H., Duramad O., Hori T., Delespesse G.J., Watanabe N., et al. TSLP-activated dendritic cells induce an inflammatory T helper type 2 cell response through OX40 ligand. JExp Med 2005, 202:1213-1223.
80. De Benedetto A., Kubo A., Beck L.A. Skin barrier disruption: a requirement for allergen sensitization?. JInvest Dermatol 2012, 132:949-963.
81. Darsow U., Laifaoui J., Kerschenlohr K., Wollenberg A., Przybilla B., Wuthrich B., et al. The prevalence of positive reactions in the atopy patch test with aeroallergens and food allergens in subjects with atopic eczema: a European multicenter study. Allergy 2004, 59:1318-1325.
82. Landheer J., Giovannone B., Mattson J.D., Tjabringa S., Bruijnzeel-Koomen C.A., McClanahan T., et al. Epicutaneous application of house dust mite induces thymic stromal lymphopoietin in nonlesional skin of patients with atopic dermatitis. JAllergy Clin Immunol 2013, 132:1252-1254.
83. Wang Y.H., Angkasekwinai P., Lu N., Voo K.S., Arima K., Hanabuchi S., et al. IL-25 augments type 2 immune responses by enhancing the expansion and functions of TSLP-DC-activated Th2 memory cells. JExp Med 2007, 204:1837-1847.
84. Owyang A.M., Zaph C., Wilson E.H., Guild K.J., McClanahan T., Miller H.R., et al. Interleukin 25 regulates type 2 cytokine-dependent immunity and limits chronic inflammation in the gastrointestinal tract. JExp Med 2006, 203:843-849.
85. Fort M.M., Cheung J., Yen D., Li J., Zurawski S.M., Lo S., et al. IL-25 induces IL-4, IL-5, and IL-13 and Th2-associated pathologies in vivo. Immunity 2001, 15:985-995.
86. Hvid M., Vestergaard C., Kemp K., Christensen G.B., Deleuran B., Deleuran M. IL-25 in atopic dermatitis: a possible link between inflammation and skin barrier dysfunction?. JInvest Dermatol 2011, 131:150-157.
87. Gudjonsson J.E., Ding J., Li X., Nair R.P., Tejasvi T., Qin Z.S., et al. Global gene expression analysis reveals evidence for decreased lipid biosynthesis and increased innate immunity in uninvolved psoriatic skin. JInvest Dermatol 2009, 129:2795-2804.
88. Matsumoto M., Sugiura H., Uehara M. Skin barrier function in patients with completely healed atopic dermatitis. JDermatol Sci 2000, 23:178-182.
89. Jensen J.M., Folster-Holst R., Baranowsky A., Schunck M., Winoto-Morbach S., Neumann C., et al. Impaired sphingomyelinase activity and epidermal differentiation in atopic dermatitis. JInvest Dermatol 2004, 122:1423-1431.
90. Di Nardo A., Wertz P., Giannetti A., Seidenari S. Ceramide and cholesterol composition of the skin of patients with atopic dermatitis. Acta Derm Venereol 1998, 78:27-30.
91. Werner Y., Lindberg M. Transepidermal water loss in dry and clinically normal skin in patients with atopic dermatitis. Acta Derm Venereol 1985, 65:102-105.
92. Hamid Q., Boguniewicz M., Leung D.Y. Differential in situ cytokine gene expression in acute versus chronic atopic dermatitis. JClin Invest 1994, 94:870-876.
93. Suarez-Farinas M., Tintle S.J., Shemer A., Chiricozzi A., Nograles K., Cardinale I., et al. Nonlesional atopic dermatitis skin is characterized by broad terminal differentiation defects and variable immune abnormalities. JAllergy Clin Immunol 2011, 127:954-964.e1-4.
94. Tintle S., Shemer A., Suarez-Farinas M., Fujita H., Gilleaudeau P., Sullivan-Whalen M., et al. Reversal of atopic dermatitis with narrow-band UVB phototherapy and biomarkers for therapeutic response. JAllergy Clin Immunol 2011, 128:583-593.e1-4.
95. Khattri S., Shemer A., Rozenblit M., Suárez-Fariñas M., Dhingra N., Czarnowicki T., et al. Cyclosporine a in atopic dermatitis modulates activated inflammatory pathways and reverses epidermal pathology. JAllergy Clin Immunol 2014, 133:1626-1634.
96. Proksch E., Folster-Holst R., Jensen J.M. Skin barrier function, epidermal proliferation and differentiation in eczema. JDermatol Sci 2006, 43:159-169.
97. Wollenberg A., Wen S., Bieber T. Phenotyping of epidermal dendritic cells: clinical applications of a flow cytometric micromethod. Cytometry 1999, 37:147-155.
98. Semper A.E., Heron K., Woollard A.C.S., Kochan J.P., Friedmann P.S., Church M.K., et al. Surface expression of Fc epsilon RI on Langerhans' cells of clinically uninvolved skin is associated with disease activity in atopic dermatitis, allergic asthma, and rhinitis. JAllergy Clin Immunol 2003, 112:411-419.
99. Wollenberg A., Ehmann L.M. Long term treatment concepts and proactive therapy for atopic eczema. Ann Dermatol 2012, 24:253-260.
100. Macheleidt O., Kaiser H.W., Sandhoff K. Deficiency of epidermal protein-bound omega-hydroxyceramides in atopic dermatitis. JInvest Dermatol 2002, 119:166-173.
101. Darsow U., Lubbe J., Taieb A., Seidenari S., Wollenberg A., Calza A.M., et al. Position paper on diagnosis and treatment of atopic dermatitis. JEur Acad Dermatol Venereol 2005, 19:286-295.
102. Wollenberg A., Bieber T. Proactive therapy of atopic dermatitis: an emerging concept. Allergy 2009, 64:276-278.
103. Berth-Jones J., Damstra R.J., Golsch S., Livden J.K., Van Hooteghem O., Allegra F., et al. Twice weekly fluticasone propionate added to emollient maintenance treatment to reduce risk of relapse in atopic dermatitis: randomised, double blind, parallel group study. BMJ 2003, 326:1367.
104. Hanifin J., Gupta A.K., Rajagopalan R. Intermittent dosing of fluticasone propionate cream for reducing the risk of relapse in atopic dermatitis patients. Br J Dermatol 2002, 147:528-537.
105. Wollenberg A., Reitamo S., Atzori F., Lahfa M., Ruzicka T., Healy E., et al. Proactive treatment of atopic dermatitis in adults with 0.1% tacrolimus ointment. Allergy 2008, 63:742-750.
106. Fukuie T., Nomura I., Horimukai K., Manki A., Masuko I., Futamura M., et al. Proactive treatment appears to decrease serum immunoglobulin-E levels in patients with severe atopic dermatitis. Br J Dermatol 2010, 163:1127-1129.
107. Bieber T., Dannenberg B., Prinz J.C., Rieber E.P., Stolz W., Braun-Falco O., et al. Occurrence of IgE-bearing epidermal Langerhans cells in atopic eczema: a study of the time course of the lesions and with regard to the IgE serum level. JInvest Dermatol 1989, 93:215-219.
108. Bieber T., de la Salle H., Wollenberg A., Hakimi J., Chizzonite R., Ring J., et al. Human epidermal Langerhans cells express the high affinity receptor for immunoglobulin E (Fc epsilon RI). JExp Med 1992, 175:1285-1290.
109. Novak N., Bieber T. The skin as a target for allergic diseases. Allergy 2000, 55:103-107.
110. Schmid P., Simon D., Simon H.U., Akdis C.A., Wuthrich B. Epidemiology, clinical features, and immunology of the "intrinsic" (non-IgE-mediated) type of atopic dermatitis (constitutional dermatitis). Allergy 2001, 56:841-849.
111. Altrichter S., Kriehuber E., Moser J., Valenta R., Kopp T., Stingl G. Serum IgE autoantibodies target keratinocytes in patients with atopic dermatitis. JInvest Dermatol 2008, 128:2232-2239.
112. Gould H.J., Sutton B.J., Beavil A.J., Beavil R.L., McCloskey N., Coker H.A., et al. The biology of IGE and the basis of allergic disease. Annu Rev Immunol 2003, 21:579-628.
113. Kabashima-Kubo R., Nakamura M., Sakabe J., Sugita K., Hino R., Mori T., et al. Agroup of atopic dermatitis without IgE elevation or barrier impairment shows a high Th1 frequency: possible immunological state of the intrinsic type. JDermatol Sci 2012, 67:37-43.
114. Wuthrich B., Schmid-Grendelmeier P. The atopic eczema/dermatitis syndrome: epidemiology, natural course, and immunology of the IgE-associated ("extrinsic") and the nonallergic ("intrinsic") AEDS. JInvestig Allergol Clin Immunol 2003, 13:1-5.
115. Mori T., Ishida K., Mukumoto S., Yamada Y., Imokawa G., Kabashima K., et al. Comparison of skin barrier function and sensory nerve electric current perception threshold between IgE-high extrinsic and IgE-normal intrinsic types of atopic dermatitis. Br J Dermatol 2010, 162:83-90.
116. Brenninkmeijer E.E.A., Spuls P.I., Legierse C.M., Lindeboom R., Smitt J.H.S., Bos J.D. Clinical differences between atopic and atopiform dermatitis. JAm Acad Dermatol 2008, 58:407-414.
117. Suarez-Farinas M., Dhingra N., Gittler J., Shemer A., Cardinale I., Strong C.D., et al. Intrinsic atopic dermatitis shows similar T(H)2 and higher T(H)17 immune activation compared with extrinsic atopic dermatitis. JAllergy Clin Immunol 2013, 132:361-370.
118. Lowes M.A., Kikuchi T., Fuentes-Duculan J., Cardinale I., Zaba L.C., Haider A.S., et al. Psoriasis vulgaris lesions contain discrete populations of Th1 and Th17 T cells. JInvest Dermatol 2008, 128:1207-1211.
119. Kryczek I., Bruce A.T., Gudjonsson J.E., Johnston A., Aphale A., Vatan L., et al. Induction of IL-17+ T cell trafficking and development by IFN-gamma: mechanism and pathological relevance in psoriasis. JImmunol 2008, 181:4733-4741.
120. Nograles K.E., Zaba L.C., Shemer A., Fuentes-Duculan J., Cardinale I., Kikuchi T., et al. IL-22-producing "T22" T cells account for upregulated IL-22 in atopic dermatitis despite reduced IL-17-producing TH17 T cells. JAllergy Clin Immunol 2009, 123:1244-1252.e2.
121. Koga C., Kabashima K., Shiraishi N., Kobayashi M., Tokura Y. Possible pathogenic role of Th17 cells for atopic dermatitis. JInvest Dermatol 2008, 128:2625-2630.
122. Yamaguchi H., Kabashima-Kubo R., Bito T., Sakabe J., Shimauchi T., Ito T., et al. High frequencies of positive nickel/cobalt patch tests and high sweat nickel concentration in patients with intrinsic atopic dermatitis. JDermatol Sci 2013, 72:240-245.
123. Tokura Y. Extrinsic and intrinsic types of atopic dermatitis. JDermatol Sci 2010, 58:1-7.
124. Miraglia del Giudice M., Decimo F., Leonardi S., Maioello N., Amelio R., Capasso A., et al. Immune dysregulation in atopic dermatitis. Allergy Asthma Proc 2006, 27:451-455.
125. Weidinger S., Rodriguez E., Stahl C., Wagenpfeil S., Klopp N., Illig T., et al. Filaggrin mutations strongly predispose to early-onset and extrinsic atopic dermatitis. JInvest Dermatol 2007, 127:724-726.
126. Akdis C.A., Akdis M. Immunological differences between intrinsic and extrinsic types of atopic dermatitis. Clin Exp Allergy 2003, 33:1618-1621.
127. Akdis M., Akdis C.A., Weigl L., Disch R., Blaser K. Skin-homing, CLA(+) memory T cells are activated in atopic dermatitis and regulate IgE by an IL-13-dominated cytokine pattern: IgG4 counter-regulation by CLA(-) memory T cells. JImmunol 1997, 159:4611-4619.
128. Suarez-Farinas M., Gittler J.K., Shemer A., Cardinale I., Krueger J.G., Guttman-Yassky E. Residual genomic signature of atopic dermatitis despite clinical resolution with narrow-band UVB. JAllergy Clin Immunol 2013, 131:577-579.
129. Behshad R., Cooper K.D., Korman N.J. Aretrospective case series review of the peroxisome proliferator-activated receptor ligand rosiglitazone in the treatment of atopic dermatitis. Arch Dermatol 2008, 144:84-88.
130. Haw S., Shin M.K., Haw C.R. The efficacy and safety of long-term oral cyclosporine treatment for patients with atopic dermatitis. Ann Dermatol 2010, 22:9-15.
131. Babu K.S., Polosa R., Morjaria J.B. Anti-IgE: emerging opportunities for Omalizumab. Expert Opin Biol Ther 2013, 13:765-777.
132. Kim J.Y., Park J.S., Park J.C., Kim M.E., Nahm D.H. Double-filtration plasmapheresis for the treatment of patients with recalcitrant atopic dermatitis. Ther Apher Dial 2013, 17:631-637.
133. Blauvelt A. T-helper 17 cells in psoriatic plaques and additional genetic links between IL-23 and psoriasis. JInvest Dermatol 2008, 128:1064-1067.
134. Kagami S., Rizzo H.L., Lee J.J., Koguchi Y., Blauvelt A. Circulating Th17, Th22, and Th1 cells are increased in psoriasis. JInvest Dermatol 2010, 130:1373-1383.
135. Suarez-Farinas M., Li K., Fuentes-Duculan J., Hayden K., Brodmerkel C., Krueger J.G. Expanding the psoriasis disease profile: interrogation of the skin and serum of patients with moderate-to-severe psoriasis. JInvest Dermatol 2012, 132:2552-2564.